Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Hypercholesterolemia is a significant risk factor for cardiovascular disease, particularly in patients with non-insulin-dependent diabetes mellitus (NIDDM).
• Effective lipid-lowering strategies are crucial for managing cardiovascular risk in this patient population.

Purpose of the Study:

• To evaluate the efficacy of simvastatin in reducing lipid levels in NIDDM patients with hypercholesterolemia.
• To monitor for any clinical and biochemical adverse effects associated with simvastatin treatment.

Main Methods:

• A 4-week placebo-controlled trial was conducted with 43 NIDDM patients diagnosed with hypercholesterolemia.
• Simvastatin dosage was escalated from 10 mg to 40 mg over 24 weeks based on total cholesterol levels.
• Patients adhered to a lipid-lowering diet and continued regular non-lipid-lowering medications.

Main Results:

• Simvastatin treatment resulted in a significant reduction in mean total cholesterol levels, ranging from 22.2% to 28.5% over the study period.
• A simvastatin dose of 10 mg demonstrated comparable total cholesterol reduction to higher doses.
• A 20 mg dose of simvastatin led to a 20.9% decrease in mean triglyceride levels.
• No significant alterations were observed in high-density lipoprotein cholesterol levels or diabetes control.

Conclusions:

• Simvastatin is an effective lipid-lowering agent for NIDDM patients with hypercholesterolemia.
• Low-dose simvastatin (10 mg) achieved significant reductions in total cholesterol.
• Simvastatin treatment did not negatively impact glycemic control or HDL-C levels in this cohort.